A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
670actual
Sites
183
Countries
Argentina, Australia, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-13 | actual | When the study began enrolling |
| Primary completion | 2024-09-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-10 | estimated | The whole study's end, after follow-up |
| First posted | 2021-06-01 | actual | When this record first appeared on the registry |
| Results posted | 2025-10-24 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriatic Arthritis
Interventions
- Drug: Deucravacitinib — also filed as BMS-986165
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With ACR 20 Response at Week 16
measured Week 16
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2024-05-06 · 13.3 MB · Prot_SAP_000.pdf
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed